Be a Smart Investor
Tuesday, June 6, 2017
Perjeta trial a setback for Roche, not a disaster: Novasecta managing partner
John Rountree, managing partner at Novasecta, discusses the fallout of a disappointing breast cancer drug trial for pharmaceutical firm Roche.
from Mergers and Acquisitions http://ift.tt/2qX1bqe
No comments:
Post a Comment
Newer Post
Older Post
Home
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment